LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunofluorescence Assay Market Worth USD 2 Billion by 2023

By LabMedica International staff writers
Posted on 02 Mar 2018
The global immunofluorescence assay market estimated to be worth USD 1.51 billion in 2018 and is projected to grow at a CAGR of 5.8% to reach USD 2.01 billion by 2023, driven by the growing prevalence of chronic diseases, increasing R&D spending, and rise in healthcare spending.

These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a global market research company.

On the basis of product, the reagents segment held the largest share of the global immunofluorescence assay market due to growing applications of biosciences and biotechnology in the pharmaceutical and healthcare fields, rising prevalence of a number of diseases, increasing R&D activities, and government initiatives to strengthen national research capabilities. On the basis of disease, the cancer segment held the largest share of the immunofluorescence assay market, driven by the increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer.

On the basis of type, the indirect immunofluorescence assay segment held the largest market share, driven by the increasing adoption of the indirect immunofluorescence technique owing to its advantages such as sensitivity, flexibility, better signal amplification, and lower cost than the direct immunofluorescence technique. On the basis of end-user, the pharmaceutical and biotechnology companies segment held the largest share of the immunofluorescence assay market, due to the increasing use of immunofluorescence assay in the study of various diseases and drug discovery & development processes in pharmaceutical and biotechnology companies.

In 2017, North America held the largest share of the global immunofluorescence assay market, followed by Europe and Asia Pacific. The large share of the North American immunofluorescence assay market is mainly due to the rising incidence of chronic & infectious diseases, increasing R&D spending, growing research activities, favorable government funding opportunities, and the presence of key players in the region.

Related Links:
MarketsandMarkets


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Repetitive Pipette
VWR® Stepper Pro
New
Prefilled Tubes
Prefilled 5.0ml Tubes

Latest Industry News

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
01 Mar 2018  |   Industry

FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
01 Mar 2018  |   Industry

CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
01 Mar 2018  |   Industry



ADLM